Generic placeholder image

Current Clinical Pharmacology

Editor-in-Chief

ISSN (Print): 1574-8847
ISSN (Online): 2212-3938

Inducing Synthetic Lethality using PARP Inhibitors

Author(s): David S. Boss, Jos H. Beijnen and Jan H.M. Schellens

Volume 5, Issue 3, 2010

Page: [192 - 195] Pages: 4

DOI: 10.2174/157488410791498798

Price: $65

Abstract

The enzyme poly(ADP)-ribose polymerase-1 (PARP-1) plays an important role in the repair of DNA damage via a mechanism called base excision repair (BER). Initially, inhibition of PARP-1 showed to be a promising anti-tumor strategy in preclinical models using BRCA1 and BRCA2 deficient tumor cell lines. More recently, several small molecules targeting PARP-1 entered the clinic and demonstrated compelling anti-tumor activity in patients with BRCA deficient breast and ovarian cancers, and in patients with triple-negative breast cancer. In this review we aim to summarize the most recent advances in the development of PARP inhibitors, with a focus on the clinical data.

Keywords: Synthetic lethality, repair mechanism, PARP, BRCA deficient, olaparib


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy